CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
LY2886721 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01133405
NCT01133405Phase 1Completed
CompareCT.gov

Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects

Eli Lilly and Company·interventional·Posted May 28, 2010·Updated Sep 16, 2019

In Brief

A Phase 1 clinical trial evaluating LY2886721 and Placebo for Alzheimer's Disease. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 28, 2010
Enrollment StartJun 1, 2010
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.1 years ago

Interventions

LY2886721drug

Oral capsules

Placebodrug

Oral capsules